Intravesical Botulinum Toxin A Injections in Treatment of Interstitial Cystitis Refractory to Conventional Treatment

Interstitial Cystitis Clinical Trial

Official title:

Intravesical Botulinum Toxin A Injection in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01969773
• Other study ID #: TCGHUROL009
• Status: Completed
• Phase: Phase 2
• First received: October 22, 2013
• Last updated: February 16, 2017
• Start date: December 2012
• Est. completion date: December 2014

Study information

• Verified date: February 2017
• Source: Buddhist Tzu Chi General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study was designed in a multicenter, randomized, double-blind, placebo controlled trial to test the actual therapeutic effects of intravesical BoNTA injection. The results of this study might provide clinical evidence for a better therapeutic regimen in the treatment of IC/PBS.

Description:

Background: Interstitial cystitis/painful bladder syndrome (IC/PBS) is a debilitating chronic disease of unknown etiology. Current treatments are usually unsuccessful in completely eradicating bladder pain and increasing bladder capacity. Although investigations on this topic have been enthusiastically performed, the etiology of IC/PBS remains unknown. Treatment based on single pathophysiology such as urothelial damage or neurogenic inflammation might not enough to eradicate the cascade of pathologies of IC/PBS.

Inhibition of neuroplasticity of the sensory fibers in the suburothelial space by intravesical BoNT-A injections might have good therapeutic targeting on pain and sensory urgency in patients with IC/PBS. In recent basic researches, BoNT-A has been shown to inhibit not only the release of acetylcholine and norepinephrine, but also that of nerve growth factor, adenosine triphosphate, substance P and calcitonin gene-related peptide from the nerve fibers and urothelium. This study was designed in a multicenter, randomized, double-blind, placebo controlled trial to test the actual therapeutic effects of intravesical BoNT-A injection on IC/PBS. The results of this study might provide clinical evidence for a better therapeutic regimen in the treatment of IC/PBS.

Materials and Methods: A total of 90 patients with IC/PBS who have failed conventional treatments for at least 6 months will be enrolled in this study. A diagnosis of IC/PBS has been established based on characteristic symptoms and cystoscopic findings of glomerulations, petechia, or mucosal fissures after hydrodistention. They will be investigated thoroughly on enrollment and will be excluded if not meeting the inclusion criteria of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). However, in this study the patients with Hunner's ulcer will not be included because previous study has shown that ulcer type IC/PBS does not respond to intravesical BoNT-A injection.

A 3-day voiding diary for functional bladder capacity, urinary frequency and nocturnal, O'Leary-Sant symptom and problem indexes, visual analog score (VAS), and videourodynamic parameters and potassium chloride (KCl) sensitivity test will be used to assess the therapeutic efficacy. Patients will be informed of the possible complications associated with BoNT-A injection such as generalized muscle weakness, difficult urination, transient urinary retention, or urinary tract infections. Eligible patients will be randomly assigned to receive intravesical injection of 100U of BoNT-A (BOTOX, Allergan, Irvine, CA, USA) (the treatment group) or injection with normal saline (control group). The intravesical injection will be performed immediately followed by cystoscopic hydrodistention under intravenous general anesthesia in the operation room.

Blood (10ml) and urine samples (30ml) will be collected before intravesical injection and after bladder hydrodistention. Bladder wall biopsies will also be performed after hydrodistention. The patients will be allocated to treatment or control group by the permuted block randomization code in 2:1 ratio, which is centrally controlled by a clinical pharmacist who prepares the solution for injection. Each vial of BoNT-A will be diluted with 10 ml of normal saline, resulting in 10U BoNT-A per 1.0 ml. Patients receive 20 suburothelial injections of BoNT-A solution or normal saline, each injection site receives 5U or saline in 0.5 ml. After the BoNT-A injections, patients will be followed up in the outpatient clinic 2 weeks and 4 weeks later. Then the patients will be followed up at out-patient clinic at 2 weeks, 4 weeks and 12 weeks. The primary end-point of this study is the reduction of bladder pain at 12-week follow-up. If patient has a reduction of VAS pain score of 2 or more, they will be considered as successfully treated. The treatment outcome will also be assessed by the global response assessment (GRA) to evaluate the overall perception of treatment result. The result will be considered as excellent when patients report improvement in the GRA by >2 or patients become free of bladder pain (VAS=0). Data will be compared between treatment and placebo groups. A p-value of less than 0.05 will be considered statistically significant.

Cystoscopy and bladder biopsy will be performed and sent for pathological examination and urological laboratory for investigations. The urine and serum biomarkers (NGF) and urothelial dysfunction markers (TUNEL for apoptosis, Ki-67 for proliferation, tryptase staining for mast cell activity, E-cadherin and zonula occludens-1 for junction protein expression) will be assessed to investigate the severity of urothelial dysfunction and chronic inflammation presented in these diseased bladders. Furthermore, the inflammatory protein assay such as TNFα, IL-6, IL-8 or TGF-beta will also be measured by protein array and western blotting. The urine and blood samples will be collected at baseline, 4 weeks, and end-point (12 weeks) in both treatment and controlled patients. The changes of urine and serum nerve growth factor (NGF) and cytokines (such as IL-1 beta, IL-6, IL-8, TNF-alpha) will be compared within group and between groups to provide laboratory evidence of decrease of bladder inflammation in IC/PBS. The changes of NGF and cytokines levels after BoNT-A injection treatments will also be compared in patients who respond and not respond to the treatment given. Urinary and serum NGF and cytokines levels were measured by the ELISA method.

Expected Results: The results of this study may demonstrate that intravesical injection of BoNT-A has a better clinical effect to provide greater pain relief and increase bladder capacity in patients with IC/PBS compared to the patients who received saline injection treatment. The clinical effect of BoNT-A on IC/PBS might be further reflected by the reduction of the serum or urinary NGF and cytokines levels.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: December 2014
• Est. primary completion date: December 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 85 Years

Eligibility

Inclusion Criteria:

• Patients with IC/PBS who have failed conventional treatments for at least 6 months will be enrolled.

• A diagnosis of IC/PBS has been established based on characteristic symptoms and cystoscopic findings of glomerulations, petechia, or mucosal fissures after hydrodistention.

• All patients have been treated with at least two types of treatment modalities including non-steroid anti-inflammatory drugs, oral pentosan polysulfate sodium (PPS), intravesical instillation of heparin, hyaluronic acid, or tricyclic antidepressant for at least 6 months but the symptoms remained unchanged or relapsed.

Exclusion Criteria:

• Exclusion criteria proposed by NIDDK

• Automatic exclusions:

1. Age <18 years old

2. Benign or malignant bladder tumors

3. Radiation cystitis Tuberculous cystitis

4. Bacterial cystitis

5. Vaginitis

6. Cyclophosphamide cystitis

7. Symptomatic urethral diverticulum

8. Uterine, cervical, vaginal, or urethral cancer

9. Active herpes

10. Bladder or lower ureteral calculi

11. Waking frequency <5 times in 12 hours

12. Nocturia <2 times

13. Symptoms relieved by antibiotics, urinary antiseptics, urinary analgesics (for example phenazopyridine hydrochloride)

14. Duration < 12 months

15. Involuntary bladder contractions (urodynamics)

16. Capacity > 400ml, absence of sensory urgency

• Automatic inclusions:

1.Hunner's ulcer

• Positive factors: (two positive factors are necessary for inclusion)

1. Pain on bladder filling relieved by emptying

2. Pain (suprapubic, pelvic, urethral, vaginal or peripheral)

3. Glomerulations on endoscopy

4. Decreased compliance on cystometrogram

5. Bladder distention is defined arbitrarily as 80 cm water pressure for 1 minute

• Use of Anticholinergic drugs, for the treatment of lower urinary tract symptoms who have an effect.

• Patients with severe cardiopulmonary disease and such as congestive heart failure, arrhythmia, poorly controlled hypertension, not able to receive regular follow-up.

• Patients with bladder outlet obstruction on enrollment.

• Patients with urinary retention, PVR=150 ml.

• Patients with uncontrolled confirmed diagnosis of acute urinary tract infection.

• Patients have laboratory abnormalities at screening including:

1. Alanine aminotransferase (ALT) > 3 x upper limit of normal range

2. Aspartate aminotransferase (AST) > 3 x upper limit of normal range.

3. Patients have abnormal serum creatinine level > 2 x upper limit of normal range.

• Can not be used in the treatment of patients with transurethral catheter treatment.

• Pregnant and lactating women or women who intend to become pregnant during the study or have myasthenia gravis, Eaton Lambert syndrome.

• Patients with any other serious disease or condition considered by the investigator not suitable for entry into the trial.

• Patients participated investigational drug trial within 1 month before entering this study.

• Written informed consent has been obtained.

• Patient who did not complete the 3-day micturition diary according to the instruction.

• Intestinal bladder augmentation patients receive angioplasty for the treatment of overactive bladder.

Related Conditions & MeSH terms

• Cystitis
• Cystitis, Interstitial
• Interstitial Cystitis

Intervention

Drug:
• Botulinum toxin A
Patients will be randomly assigned to receive intravesical injection of 100U of BoNT-A (BOTOX, Allergan, Irvine, CA, USA)
• Normal saline instillation
Patients will be randomly assigned to receive intravesical injection of injection with normal saline.

Locations

Country	Name	City	State
Taiwan	Buddhist Tzu Chi General Hospital	Hualien

Sponsors (1)

Lead Sponsor	Collaborator
Buddhist Tzu Chi General Hospital

Country where clinical trial is conducted

Taiwan, 

References & Publications (31)

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A; Standardisation Sub-committee of the International Continence Society.. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-78. — View Citation

Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, Dasgupta P, Fowler CJ, Anand P. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005 Sep;174(3):977-82; discussion 982-3. — View Citation

Beltinger J, McKaig BC, Makh S, Stack WA, Hawkey CJ, Mahida YR. Human colonic subepithelial myofibroblasts modulate transepithelial resistance and secretory response. Am J Physiol. 1999 Aug;277(2 Pt 1):C271-9. — View Citation

Brady CM, Apostolidis AN, Harper M, Yiangou Y, Beckett A, Jacques TS, Freeman A, Scaravilli F, Fowler CJ, Anand P. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int. 2004 Apr;93(6):770-6. — View Citation

Cayan S, Coskun B, Bozlu M, Acar D, Akbay E, Ulusoy E. Botulinum toxin type A may improve bladder function in a rat chemical cystitis model. Urol Res. 2003 Feb;30(6):399-404. — View Citation

Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB. Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol. 2004 Oct;172(4 Pt 1):1529-32. — View Citation

Chung SD, Kuo YC, Kuo HC. Intravesical onabotulinumtoxinA injections for refractory painful bladder syndrome. Pain Physician. 2012 May-Jun;15(3):197-202. — View Citation

Cockayne DA, Hamilton SG, Zhu QM, Dunn PM, Zhong Y, Novakovic S, Malmberg AB, Cain G, Berson A, Kassotakis L, Hedley L, Lachnit WG, Burnstock G, McMahon SB, Ford AP. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature. 2000 Oct 26;407(6807):1011-5. — View Citation

Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004 Jan;107(1-2):125-33. — View Citation

Dell JR, Parsons CL. Multimodal therapy for interstitial cystitis. J Reprod Med. 2004 Mar;49(3 Suppl):243-52. Review. — View Citation

Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol. 2006 Apr;49(4):704-9. — View Citation

Giannantoni A, Di Stasi SM, Nardicchi V, Zucchi A, Macchioni L, Bini V, Goracci G, Porena M. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol. 2006 Jun;175(6):2341-4. — View Citation

Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J Urol. 2008 Mar;179(3):1031-4. doi: 10.1016/j.juro.2007.10.032. — View Citation

Hanno PM, Buehler J, Wein AJ. Use of amitriptyline in the treatment of interstitial cystitis. J Urol. 1989 Apr;141(4):846-8. — View Citation

Hanno PM, Sant GR. Clinical highlights of the National Institute of Diabetes and Digestive and Kidney Diseases/Interstitial Cystitis Association scientific conference on interstitial cystitis. Urology. 2001 Jun;57(6 Suppl 1):2-6. — View Citation

Khera M, Somogyi GT, Kiss S, Boone TB, Smith CP. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int. 2004 Dec;45(7):987-93. — View Citation

Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology. 2005 Jul;66(1):94-8. — View Citation

Kuo HC. Preliminary results of suburothelial injection of botulinum a toxin in the treatment of chronic interstitial cystitis. Urol Int. 2005;75(2):170-4. — View Citation

Liu HT, Kuo HC. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology. 2007 Sep;70(3):463-8. — View Citation

Lubeck DP, Whitmore K, Sant GR, Alvarez-Horine S, Lai C. Psychometric validation of the O'leary-Sant interstitial cystitis symptom index in a clinical trial of pentosan polysulfate sodium. Urology. 2001 Jun;57(6 Suppl 1):62-6. — View Citation

Nickel JC, Barkin J, Forrest J, Mosbaugh PG, Hernandez-Graulau J, Kaufman D, Lloyd K, Evans RJ, Parsons CL, Atkinson LE; Elmiron Study Group.. Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology. 2005 Apr;65(4):654-8. — View Citation

Parsons CL, Housley T, Schmidt JD, Lebow D. Treatment of interstitial cystitis with intravesical heparin. Br J Urol. 1994 May;73(5):504-7. — View Citation

Payne CK, Mosbaugh PG, Forrest JB, Evans RJ, Whitmore KE, Antoci JP, Perez-Marrero R, Jacoby K, Diokno AC, O'Reilly KJ, Griebling TL, Vasavada SP, Yu AS, Frumkin LR; ICOS RTX Study Group (Resiniferatoxin Treatment for Interstitial Cystitis).. Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial. J Urol. 2005 May;173(5):1590-4. — View Citation

Rapp DE, Turk KW, Bales GT, Cook SP. Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol. 2006 Mar;175(3 Pt 1):1138-42. — View Citation

Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, Burgdörfer H, Göcking K, Madersbacher H, Schumacher S, Richter R, von Tobel J, Schurch B. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 2004 Apr;45(4):510-5. — View Citation

Sairanen J, Forsell T, Ruutu M. Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A. J Urol. 2004 Jun;171(6 Pt 1):2138-41. — View Citation

Sant GR, Propert KJ, Hanno PM, Burks D, Culkin D, Diokno AC, Hardy C, Landis JR, Mayer R, Madigan R, Messing EM, Peters K, Theoharides TC, Warren J, Wein AJ, Steers W, Kusek JW, Nyberg LM; Interstitial Cystitis Clinical Trials Group.. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 2003 Sep;170(3):810-5. — View Citation

Seki S, Erickson KA, Seki M, Nishizawa O, Igawa Y, Ogawa T, de Groat WC, Chancellor MB, Yoshimura N. Elimination of rat spinal neurons expressing neurokinin 1 receptors reduces bladder overactivity and spinal c-fos expression induced by bladder irritation. Am J Physiol Renal Physiol. 2005 Mar;288(3):F466-73. — View Citation

Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology. 2004 Nov;64(5):871-5; discussion 875. — View Citation

Steers WD, Tuttle JB. Mechanisms of Disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol. 2006 Feb;3(2):101-10. Review. — View Citation

Vizzard MA. Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. Exp Neurol. 2000 Jan;161(1):273-84. — View Citation

* Note: There are 31 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Net change of Patient Perception of Visual Analogue Scale (VAS)	Efficacy: The primary end-point of this study is the reduction of bladder pain at 8-week follow-up. If patient has a reduction of VAS pain score of 2 or more, they will be considered as successfully treated at baseline and 8 weeks after BoNT-A injection within and between the treatment group and control groups.; Safety: Systemic adverse events	Baseline and 8 weeks
Secondary	Net change of Patient Perception of global response assessment (GRA)	Efficacy: The treatment outcome will be assessed by the global response assessment (GRA) to evaluate the overall perception of treatment resultant at baseline and 8 weeks after BoNT-A injection within and between the treatment group and control groups.; Safety: Systemic adverse events	Baseline and 8 weeks
Secondary	Net change of O'Leary-Sant symptom and problem indexes	Efficacy: The IC symptoms will be assessed by the O'Leary-Sant symptom and problem indexes at baseline and 8 weeks after BoNT-A injection within and between the treatment group and control groups.; Safety: Systemic adverse events	Baseline and 8 weeks
Secondary	Net change of the functional bladder capacity (FBC)	Efficacy: Patients will be requested to keep a 3-day voiding diary prior to treatment to record the functional bladder capacity (FBC). Then the patients will be followed up at out-patient clinic at 8 weeks.; Safety: Systemic adverse events	Baseline and 8 weeks
Secondary	Net change of the number of urinary frequency	Efficacy: Patients will be requested to keep a 3-day voiding diary prior to treatment to record the number of urinary frequency at baseline and 8 weeks after BoNT-A injection within and between the treatment group and control groups.; Safety: Systemic adverse events	Baseline and 8 weeks
Secondary	Net change of the number of nocturnal	Efficacy: Patients will be requested to keep a 3-day voiding diary prior to treatment to record the number of nocturnal at baseline and 8 weeks after BoNT-A injection within and between the treatment group and control groups.; Safety: Systemic adverse events	Baseline and 8 weeks
Secondary	Net change of the Quality of Life (QoL)	Efficacy: Efficacy measured the net change of the Quality of Life (QoL) at baseline and 8 weeks after BoNT-A injection within and between the treatment group and control groups.; Safety: Systemic adverse events	Baseline and 8 weeks
Secondary	Net change of the maximal flow rate (Qmax)	Efficacy: Efficacy measured the net change of the maximal flow rate (Qmax) at baseline and 8 weeks after BoNT-A injection within and between the treatment group and control groups.; Safety: Systemic adverse events	Baseline and 8 weeks
Secondary	Net change of the voided volume	Efficacy: Efficacy measured the net change of the voided volume at baseline and 8 weeks after BoNT-A injection within and between the treatment group and control groups.; Safety: Systemic adverse events	Baseline and 8 weeks
Secondary	Net change of the residual urine volume (PVR)	Efficacy: Efficacy measured the net change of the residual urine volume (PVR) at baseline and 8 weeks after BoNT-A injection within and between the treatment group and control groups.; Safety: Systemic adverse events	Baseline and 8 weeks